ACTIVE_NOT_RECRUITING

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a decentralized clinical trial (DCT) design in which individuals can participate from anywhere in the United States. Recruitment efforts will be designed to obtain a geographically and demographically diverse study sample.

Official Title

Curcumin, Resveratrol, and Stinging Nettle as Treatments for Gulf War Illness

Quick Facts

Study Start:2023-05-31
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05377242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Meets Kansas GWI Case Definition
  2. * Meets CDC GWI Case Definition
  3. * Able to commit to a 10-month study
  1. * Currently involved in an experimental treatment study
  2. * Abnormal liver function values
  3. * Abnormal kidney function values
  4. * Currently pregnant
  5. * Blood clotting disorder (contraindicated with all three botanicals)
  6. * Reported diagnosis of diabetes with an A1C greater than 9
  7. * The use of contraindicated medications (see below):
  8. * Anticoagulant medications (such as warfarin, heparin, etc.)
  9. * Lithium
  10. * Tacrolimus (Prograf)
  11. * Cancer medications (Alkylating agents, antitumor antibiotics, Topoisomerase I inhibitors, Tamoxifen)

Contacts and Locations

Principal Investigator

Jarred Younger, PhD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

The University of Alabama at Birmingham
Birmingham, Alabama, 35233
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Jarred Younger, PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-31
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2023-05-31
Study Completion Date2026-06-30

Terms related to this study

Keywords Provided by Researchers

  • Gulf War Illness
  • Botanicals
  • Remote
  • Clinical Trial
  • Curcumin
  • Resveratrol
  • Stinging Nettle

Additional Relevant MeSH Terms

  • Gulf War Illness